← boardnext 2026-09-21
CRDL
Cardiol Therapeutics Inc.distress 4/10 · elevated risk$1.270%today-22% from 52w high
Lead: Recurrent Pericarditis
Revenue
pre-revenue
Liquidity
$28M
Runway
1.2 yrs
Shares 1y
0%
Price & events
+22.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.4%
1D
+3.7%
1W
+21.4%
1M
-6.3%
3M
+22.6%
6M
-11.5%
1Y
-46.2%
2Y
-41.4%
5Y
-40.5%
All
Overview
- Market Cap
- $127.83M
- Volume
- 56.95K
- 52 Week Range
- $0.93 – $1.63
- Total Shares
- 100.26M
- Float Shares
- 96.50M
- Short %
- 1.98%
- % Held by Insiders
- 2.38%
- % Held by Institutions
- 24.66%
- RVOL
- 0.09x
- Beta
- 0.51
Pipeline stages · 1 programs
CardiolRx
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 1 upcoming
Catalyst news & presentations · 1
- 2026-08-13earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $7 (+471% upside) · 4 analysts
- 2026-07-14HC Wainwright & Co.Buy
- 2026-04-06Canaccord GenuityBuy
- 2026-02-10HC Wainwright & Co.Buy
- 2025-12-01HC Wainwright & Co.Buy
- 2025-06-02HC Wainwright & Co.Buy
- 2025-04-16HC Wainwright & Co.Buy
Competitors — Recurrent Pericarditis
- KNSAKiniksa Pharmaceuticals International, plc— · D0
Recent news
- 2026-07-21What's Going On With Cardiol Therapeutics Inc Class A Stock Monday? - Wealth Awesome
- 2026-07-20Why Cardiol Therapeutics Inc Class A stock is sliding today - Wealth Awesome
- 2026-07-16CRDL Stock Price, Quote & Chart - ChartMill
- 2026-07-15H.C. Wainwright reiterates Cardiol Therapeutics stock Buy rating at $9 By Investing.com - Investing.com Nigeria
- 2026-07-14Cardiol Therapeutics’ Phase II Pericarditis Data in JAHA Bolsters Near-Complete Phase III MAVERIC Trial - TipRanks
- 2026-07-14Cardiol publishes phase II pericarditis study in medical journal - Investing.com UK
- 2026-07-14Cardiol Publishes Phase II MAVERIC Data in the Journal of the American Heart Association - the deep dive
- 2026-07-14CRDL Reiterated by HC Wainwright & Co. -- Price Target Maintained at $9 - GuruFocus
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.